BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260602
DTEND;VALUE=DATE:20260610
DTSTAMP:20260514T224125
CREATED:20260211T102827Z
LAST-MODIFIED:20260211T102827Z
UID:42871-1780358400-1781049599@www.pharmajournalist.com
SUMMARY:5th ALS Drug Development Summit
DESCRIPTION:The 5th ALS Drug Development Summit returns to Boston as the ultimate platform honing industry R&D for safer\, more effect and patient-relevant drugs that serve the community\, driving a cure for sporadic and familial ALS. \nWith a brand-new agenda spanning early target exploration through to clinical design\, biomarker strategy\, and regulatory engagement\, attendees will gain comprehensive insights into genetically validated targets\, the evolving biology of TDP 43\, adaptive trial design\, and embedding the patient voice throughout development. \nJoin us for 3 days of unmissable data-driven content\, with 2 tracks spanning discovery to access for the whole team: \nTrack A: Discovery\, Preclinical & Translational – designed for CSOs\, pre-clinical researchers\, discovery scientists\, directors of biology and research\, novel modality scientists\, in viva/in vitro modelling experts and many more\, connect with an intimate group of discovery and preclinical experts for a more discursive session. \nTrack B: Clinical & Regulatory – tailor-made for medical directors\, CMOs\, clinical program leaders\, translational and clinical development heads and clinicians and more; share expertise from diverse clinical challenges and innovation in ALS. \nDesigned for biotech\, pharma\, academia\, and patient advocacy stakeholders\, this unique forum will unite 100+ senior experts and 30+ speakers from companies including AbbVie\, Biogen\, Novartis\, Eli Lilly\, QurAlis\, Prilenia\, Sanofi\, and many more. \nDiscover the full 2026 event guide now to explore all speakers and sessions – https://ter.li/28a6lw
URL:https://www.pharmajournalist.com/event/5th-als-drug-development-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260602
DTEND;VALUE=DATE:20260605
DTSTAMP:20260514T224125
CREATED:20260224T131937Z
LAST-MODIFIED:20260224T132421Z
UID:42974-1780358400-1780617599@www.pharmajournalist.com
SUMMARY:5th Extrahepatic Lipid-Based Nanoparticles Delivery Summit
DESCRIPTION:The 5th Extrahepatic Lipid-Based Nanoparticles Delivery Summit returns to Boston in June 2026 as the premier industry forum dedicated to advancing extrahepatic LNP delivery and next-generation targeted lipid nanoparticle technologies. As the field moves beyond liver-focused delivery\, achieving precise\, selective\, tissue-specific targeting remains one of the most critical challenges in genetic medicine. With growing industry validation – including strategic acquisitions by AbbVie and Bristol Myers Squibb – confidence in targeted LNP platforms is accelerating across biopharma. \nOver 3 content-rich days\, 60+ experts from leading biotech\, pharma\, and academia will share cutting-edge data and practical insights on delivering mRNA\, RNA\, gene-editing\, and cell therapy payloads to extrahepatic tissues\, including immune cells\, muscle\, and adipose tissue. Attendees will explore novel targeting ligands\, active and passive targeting strategies\, innovative lipid chemistries\, and advanced formulation approaches designed to improve biodistribution\, potency\, and safety profiles. \nThe summit will also address critical translational challenges\, including targeted LNP analytics\, scalability\, manufacturability\, and immunogenicity – key hurdles in advancing extrahepatic delivery toward clinical success. Through 13+ data-driven case studies\, 6 interactive workshops\, expert panel discussions\, and dedicated networking sessions\, participants will gain actionable strategies to accelerate development timelines and de-risk clinical progression. \nWith representation from pioneering organizations across the delivery ecosystem\, this meeting provides a unique opportunity to benchmark progress\, forge strategic partnerships\, and overcome bottlenecks limiting cell-specific LNP performance. Whether optimizing formulation\, engineering targeting ligands\, refining preclinical models\, or preparing for clinical translation\, this summit delivers the technical depth required to stay at the forefront of innovation. \nVisit Our Website for More Information. \nhttps://ter.li/rt2poz
URL:https://www.pharmajournalist.com/event/5th-extrahepatic-lipid-based-nanoparticles-delivery-summit/
LOCATION:Hotel AKA Boston Common\, 90 Tremont Street\, Boston\, MA\, 02108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260602
DTEND;VALUE=DATE:20260605
DTSTAMP:20260514T224125
CREATED:20260430T111933Z
LAST-MODIFIED:20260430T111933Z
UID:43436-1780358400-1780617599@www.pharmajournalist.com
SUMMARY:10th R&D Procurement & Sourcing in Pharma Summit
DESCRIPTION:The Future of R&D Procurement Excellence Starts Here! \nThe 10th R&D Procurement & Sourcing in Pharma Summit returns to Boston in June 2026 as the definitive meeting place for procurement\, sourcing and category management leaders across pre‑clinical and clinical R&D. This flagship event is designed to support procurement teams as they transition from transactional buying to strategic\, value‑driven partnership models that accelerate pipeline delivery and protect business continuity. \nBringing together senior R&D procurement leaders from global biopharma\, the summit focuses on strengthening sourcing resilience\, maximising CRO and CMO partnerships\, embedding AI and orchestration tools\, and aligning procurement strategy with scientific and operational ambition across the development lifecycle. \nVisionary Faculty Includes: \n\nNovartis – Strengthening global sourcing resilience amid geopolitical and supply‑chain disruption\nRegeneron Pharmaceuticals – Optimising supplier governance and long‑term strategic partnerships\nVertex Pharmaceuticals – Integrating data\, technology and AI to streamline R&D procurement operations\nTakeda & UCB – Elevating procurement’s influence through early‑stage R&D decision‑making\n\nWhy Attend? \n\nThree days of immersive learning across discovery\, pre‑clinical and clinical procurement tracks\n30+ expert speakers sharing real‑world case studies and practical\, execution‑ready frameworks\nDedicated sessions on AI‑enabled procurement\, supplier relationship management and global sourcing resilience\nExtensive networking opportunities with peers shaping the future of R&D procurement and sourcing\n\nJoin us in Boston to help redefine procurement as a strategic engine for R&D innovation\, delivering speed\, resilience and measurable supplier value across the development pipeline.
URL:https://www.pharmajournalist.com/event/10th-rd-procurement-sourcing-in-pharma-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260608
DTEND;VALUE=DATE:20260611
DTSTAMP:20260514T224125
CREATED:20260320T110845Z
LAST-MODIFIED:20260320T110845Z
UID:43192-1780876800-1781135999@www.pharmajournalist.com
SUMMARY:PFS & Injectable Drug Delivery West Coast
DESCRIPTION:Foster Innovation and Collaboration at the 10th Annual Pre-Filled Syringes and Injectable Drug Devices West Coast Conference! \nJoin us in June 2026 as SAE Media Group’s renowned West Coast event returns\, bringing together biotech pioneers\, pharma leaders\, and device innovators to shape the future of injectable drug delivery. \nThis year’s conference will bring a brand NEW focus day followed by the two-day main conference offering an unparalleled platform to explore cutting-edge advances in combination product technology while fostering collaboration between pharma\, device developers\, and regulators. \nFree to Attend for Pharma and Biotech!* \nWhat You’ll Gain: \n\nActionable insights to strengthen your drug-device portfolio.\nOpportunities to network with key players shaping the injectable drug delivery landscape.\nA future-focused perspective on innovation\, regulation\, and patient-centric care.\nThis must-attend event is your chance to stay ahead in the rapidly evolving injectable drug delivery space. We look forward to welcoming you to the West Coast in June 2026!\nJoin organizations including: AbbVie\, Amgen\, Bristol Myers Squibb\, Ionis Pharmaceuticals\, Protagonist Therapeutics\, Genentech and\, more\n\n*Terms and Conditions apply \nTo learn more and register\, please click here.
URL:https://www.pharmajournalist.com/event/pfs-injectable-drug-delivery-west-coast/
LOCATION:SAN DIEGO MARRIOTT LA JOLLA\, 4240 La Jolla Village Drive\, La Jolla\, San Diego\, CA\, 92037\, United States
ORGANIZER;CN="SAE Media Group":MAILTO:marketingteamlondon@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260609
DTEND;VALUE=DATE:20260612
DTSTAMP:20260514T224125
CREATED:20260224T133550Z
LAST-MODIFIED:20260224T133750Z
UID:42982-1780963200-1781222399@www.pharmajournalist.com
SUMMARY:5th World ADC Summit South Korea
DESCRIPTION:The 5th World ADC Summit South Korea (previously World ADC Asia)\, taking place 9–11 June 2026 in Seoul\, stands as the Asia’s premier meeting dedicated to accelerating next‑generation antibody–drug conjugate (ADC) development. \nAs South Korea rapidly transitions from a biosimilar‑focused market to a global innovator in precision oncology\, ADCs have emerged as a centrepiece of this shift. The summit responds to this momentum by offering a comprehensive\, end‑to‑end forum covering discovery\, preclinical development\, clinical translation\, and CMC innovation. With more than 300 industry experts expected to attend\, the event brings together leading organizations to exchange insights on novel and dual‑payloads\, bispecific ADCs\, and strategies to overcome Topo‑1 resistance and develop best‑in‑class ADCs. \nWhether you are an expert or beginner in the field\, join one of our three content tracks spanning early discovery through manufacturing scale‑up to get up to speed with the latest developments. \nOne Pass\, Three Events: Part of the World Targeted Therapeutics Summit in South Korea organized by Hanson Wade\, this is your opportunity to converge with peers working on targeted protein degradation (TPDs)\, Bispecifics\, and T-cell engagers\, who aim to turn South Korea into the next major global hub for biopharma innovation in targeted therapeutics. \nTo know more visit: https://ter.li/qznxdj
URL:https://www.pharmajournalist.com/event/5th-world-adc-summit-south-korea/
LOCATION:COEX Magok Lewest\, 143 Magokjungang-ro\, Gangseo-gu\, Seoul\, South Korea
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260609
DTEND;VALUE=DATE:20260612
DTSTAMP:20260514T224125
CREATED:20260224T135246Z
LAST-MODIFIED:20260224T135246Z
UID:42990-1780963200-1781222399@www.pharmajournalist.com
SUMMARY:World TPD & Induced Proximity Summit South Korea
DESCRIPTION:The World TPD & Induced Proximity Summit South Korea is the first and only Asian industry event dedicated exclusively to advancing targeted protein degradation (TPD) and induced proximity–based therapeutics. \nAs the global TPD field enters a pivotal era\, with the first PROTAC approval on the horizon and multiple candidates progressing through clinical trials\, South Korea has emerged as a major innovation hub\, fuelled by rapid investment\, strategic partnerships\, and an expanding biotech ecosystem. \nDesigned as an end‑to‑end forum for degraders\, molecular glues\, and degrader antibody conjugates (DACs)\, the summit brings together international opinion leaders and Korean pioneers to address discovery challenges\, translational strategy\, clinical development\, and emerging platform technologies. Deep‑dive sessions explore novel E3 ligases\, AI‑enabled discovery workflows\, proteomics‑driven target identification\, PK/PD optimization\, and case studies showcasing first‑in‑human PROTAC and DAC programs. \nOne Pass\, Three Events: Part of the World Targeted Therapeutics Summit in South Korea organized by Hanson Wade\, this is your opportunity to converge with peers working on antibody-drug conjugates (ADCs)\, Bispecifics\, and T-cell engagers\, who aim to turn South Korea into the next major global hub for biopharma innovation in targeted therapeutics. \nTo know more visit: https://ter.li/tslwfl
URL:https://www.pharmajournalist.com/event/world-tpd-induced-proximity-summit-south-korea/
LOCATION:COEX Magok Lewest\, 143 Magokjungang-ro\, Gangseo-gu\, Seoul\, South Korea
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260609
DTEND;VALUE=DATE:20260612
DTSTAMP:20260514T224125
CREATED:20260224T135629Z
LAST-MODIFIED:20260224T135659Z
UID:42993-1780963200-1781222399@www.pharmajournalist.com
SUMMARY:World Bispecific & T-Cell Engager Summit South Korea
DESCRIPTION:The World Bispecific & T‑Cell Engager Summit South Korea is Asia’s first and only industry‑dedicated forum focused on advancing bispecific antibodies and T‑cell engagers (TCEs)\, modalities that are redefining the therapeutic landscape for solid tumors and immune‑driven diseases. Propelled by landmark regulatory approvals such as tarlatamab and ivonescimab\, bispecifics and TCEs have captured global interest for their ability to address previously unmet medical needs. \nThis inaugural summit brings together international experts and regional leaders for deep‑dive sessions on advanced engineering\, co-stimulation strategies\, antibody masking\, conditional activation\, and the design of trispecific and tetraspecific formats. The agenda also explores bispecific ADCs (bsADCs)\, novel target selection\, TCE expansion into autoimmune disease\, translational biology\, and early clinical readouts shaping development priorities. \nAs South Korea positions itself as a rising global powerhouse in targeted therapeutics\, this summit provides a vital forum for advancing first‑in‑class bispecific and TCE‑based therapies with the potential to transform patient outcomes worldwide. \nOne Pass\, Three Events: Part of the World Targeted Therapeutics Summit in South Korea organized by Hanson Wade\, this is your opportunity to converge with peers working on antibody-drug conjugates (ADCs)\, Bispecifics\, and T-cell engagers\, who aim to turn South Korea into the next major global hub for biopharma innovation in targeted therapeutics. \nTo know more visit: https://ter.li/bw174h
URL:https://www.pharmajournalist.com/event/world-bispecific-t-cell-engager-summit-south-korea/
LOCATION:COEX Magok Lewest\, 143 Magokjungang-ro\, Gangseo-gu\, Seoul\, South Korea
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260623
DTEND;VALUE=DATE:20260626
DTSTAMP:20260514T224125
CREATED:20260313T132352Z
LAST-MODIFIED:20260313T132352Z
UID:43137-1782172800-1782431999@www.pharmajournalist.com
SUMMARY:8th T-Cell Engager Therapeutics Summit
DESCRIPTION:8th T‑Cell Engager Therapeutics Summit — Your Flagship TCE Meeting \nThe T‑cell engager field is evolving at an unprecedented pace. With multiple clinical approvals now validating the durability and therapeutic relevance of this modality\, and a new wave of next‑generation solid tumor and autoimmune programs rapidly progressing toward the clinic\, TCEs have firmly established themselves as one of the most transformative forces shaping the future of immunotherapy. \nOver the past year\, the landscape has seen a sharp rise in investment\, strategic alliances\, and high‑value partnerships. Landmark collaborations\, including BMS × JanuX Therapeutics\, Candid Therapeutics × WuXi Biologics\, and AbbVie × EvolveImmune\, underscore the growing confidence in immune‑redirecting platforms and the sector’s commitment to accelerating innovation across oncology and autoimmune disease. \nNow moving from Boston to San Diego for 2026\, the 8th T‑Cell Engager Therapeutics Summit remains the industry’s most comprehensive end‑to‑end meeting dedicated exclusively to advancing\, optimizing\, and translating TCEs. This case‑study‑driven forum equips engineering\, discovery\, R&D\, translational\, and clinical development teams with the actionable insights needed to design safer\, more potent\, durable\, and precisely targeted TCEs for solid tumors. The agenda also shines a spotlight on new applications expanding engager biology into autoimmune and inflammatory indications. \nIf accelerating your TCE pipeline is a priority\, this is the meeting you cannot afford to miss. \nWhat’s New in 2026? \nTwo Brand‑New Parallel Tracks\nTailor your learning across two dedicated streams: Discovery & Engineering and Preclinical to Clinical Translation\, enabling deep dives aligned to your role and pipeline stage. \nFresh Clinical Insights in Combination & Precision Immunotherapy\nHear directly from Amgen and Regeneron as they reveal new clinical evidence on chemo‑immunotherapy integration\, co‑stimulation pairings\, and combination‑ready TCE design for deeper\, more durable responses in solid tumors. \nExplore the Full Event Guide \n120+ Industry Attendees\n28+ Expert Speakers\n8+ Hours of Networking\n6 Deep‑Dive Workshops\n1 Modality at the Center\nThe Only Forum Advancing TCEs Across Oncology & Autoimmune Disease \nView the Full Program – See all sessions\, speakers\, and workshops: https://ter.li/fulua0
URL:https://www.pharmajournalist.com/event/8th-t-cell-engager-therapeutics-summit/
LOCATION:The Westin San Diego Bayview\, 400 W Broadway\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR